Findings from the ECLIPSE and BLUE-C studies
Evidence for efficacy is based on the results from the CheckMate 901 study
Findings from the final distant metastasis-free survival analysis of KEYNOTE-716 study
It is indicated in adult patients at high risk for recurrence
Findings from the FIRSTMAPPP study